Grace Therapeutics, Inc. (GRCE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GRCE currently has 14.1M outstanding shares. with significant dilution risk as 8.86M authorized shares could dilute existing holders by 62.7%. The company has significantly diluted shareholders by 53.23% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 13, 2025 |
10-Q filing | 14.1M shares outstanding |
14M | 8.9M |
| Jun 23, 2025 |
10-K filing | 13.8M shares outstanding |
14M | 8.9M |
| Mar 10, 2025 |
S-3 filing: This S-3 filing relates to the resale of up to 8,836,584 shares of common stock by selling stockholders, comprised of shares and warrant shares issuable upon the exercise of warrants. |
10M | 8.9M |
| Feb 13, 2025 |
10-Q filing | 10.1M shares outstanding |
10M | 19K |
| Nov 13, 2024 |
10-Q filing | 10.1M shares outstanding |
10M | 19K |
| Oct 08, 2024 |
POS AM filing: This is a post-effective amendment to a registration statement on Form S-3 filed by Acasti Pharma Inc. relating to a shelf offering of common stock. The amendment reflects the company's change of jurisdiction from Quebec to British Columbia to Delaware. |
11M | 19K |
| Aug 09, 2024 |
10-Q filing | 10.9M shares outstanding |
11M | 6.6M |
| Jun 21, 2024 |
10-K filing | 9.5M shares outstanding |
9.5M | 6.6M |
| Feb 12, 2024 |
10-Q filing | 9.4M shares outstanding |
9.4M | 6.6M |
| Nov 13, 2023 |
10-Q filing | 9.4M shares outstanding |
9.4M | 6.6M |
| Oct 06, 2023 |
S-3 filing: This prospectus relates to the resale by selling shareholders of up to 6,594,615 common shares. |
7.4M | 6.6M |
| Aug 11, 2023 |
10-Q filing | 7.4M shares outstanding |
7.4M | 19K |
| Jul 10, 2023 |
Stock Split
8-K filing: Stock split 1-for-6 | Outstanding: 44,612,831 → 7,435,471 |
7.4M | 3.2K |
| Jun 23, 2023 |
10-K filing | 44.6M shares outstanding |
45M | 120K |
| Feb 14, 2023 |
10-Q filing | 44.6M shares outstanding |
45M | 120K |
| Nov 14, 2022 |
10-Q filing | 44.6M shares outstanding |
45M | 120K |
| Aug 11, 2022 |
10-Q filing | 44.3M shares outstanding |
44M | 120K |
| Jun 21, 2022 |
10-K filing | 44.4M shares outstanding |
44M | 120K |
| Feb 14, 2022 |
10-Q filing | 44.3M shares outstanding |
44M | 120K |
| Nov 10, 2021 |
10-Q filing | 44.3M shares outstanding |
44M | 120K |
| Aug 31, 2021 |
Stock Split
8-K filing: Stock split 1-for-8 | Outstanding: 208,375,549 → 44,288,177 |
44M | 920K |
| Aug 27, 2021 |
Stock Split
8-K filing: Stock split 1-for-8 | Outstanding: 208,375,549 → 26,046,943 |
26M | 920K |
| Aug 12, 2021 |
10-Q filing | 208.4M shares outstanding |
210M | 7.4M |
| Jun 22, 2021 |
10-K filing | 208.4M shares outstanding |
210M | 7.4M |
| Mar 09, 2021 |
8-K filing: Acasti Pharma Inc. issued 20,159,229 common shares through an at-the-market equity offering program for gross proceeds of US$21.7 million. ($21.7M proceeds) |
200M | 7.4M |
| Feb 09, 2021 |
10-Q filing | 179.5M shares outstanding |
180M | 7.4M |
| Jan 27, 2021 |
8-K filing: Acasti Pharma Inc. issued 82,626,562 common shares through an at-the-market equity offering program, generating gross proceeds of US$28.5 million. ($28.5M proceeds) |
97M | 7.4M |
| Nov 16, 2020 |
10-Q filing | 96.9M shares outstanding |
97M | 7.4M |
| Aug 13, 2020 |
10-Q filing | 96.9M shares outstanding |
97M | 7.4M |
| Jun 29, 2020 |
S-3 filing: Acasti Pharma Inc. may offer and sell from time to time up to an aggregate of US$200,000,000 of common shares (issued separately or upon exercise of warrants), warrants and units comprising any combination of common shares and warrants. |
N/A | 7.4M |
| Jun 29, 2020 |
10-K filing | 92.5M shares outstanding |
92M | 7.4M |